Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Facts and controversies in the use of trastuzumab in the adjuvant setting.

Nature clinical practice. Oncology - 1 Nov 2008

Dinh Phuong, de Azambuja Evandro, Cardoso Fatima, Piccart-Gebhart Martine J

Abstract excerpt

The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% of breast cancer patients, and this feature is associated with an aggressive phenotype, high recurrence rate and reduced survival. Until recently, combination chemotherapy (with or without endocrine therapy) was the only effective adjuvant treatment for HER2-positive patients. Trastuzumab is a monoclonal antibody...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Belgium
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cost-Benefit Analysis

Share to Neoplasm Recurrence, Local

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 18779850
DOI: 10.1038/ncponc1219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Facts and controversies in the use of trastuzumab in the adjuvant setting.PMID 18779850Read ↗

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.Semantic proximity Read ↗

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.Semantic proximity Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Translating neoadjuvant therapy into survival benefits: one size does not fit all.Semantic proximity Read ↗

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast CancerSemantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.Semantic proximity Read ↗

Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) StudySemantic proximity Read ↗

The Evolving Landscape of HER2 Targeting in Breast Cancer.Semantic proximity Read ↗

Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes.Semantic proximity Read ↗

The new millennium for adjuvant therapy in breast cancer.Semantic proximity Read ↗

De-escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.